Courtney D. DiNardo

Courtney D. DiNardo, MD, MSCE is Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, where she is recognized as one of the foremost clinical investigators in IDH-mutated AML and a leading pioneer in the development of novel AML therapies. Dr. DiNardo was the lead investigator in the pivotal clinical development of enasidenib (AG-221), the first IDH2 inhibitor, and ivosidenib (AG-120), the first IDH1 inhibitor, in AML. She led the AG221-C-001 phase I/II study of enasidenib in IDH2-mutated relapsed/refractory AML (Blood 2017), demonstrating a 40.3% overall response rate and characterizing the unique differentiation syndrome associated with IDH inhibitors. She subsequently led the phase III AG221-AML-005 trial and AG-120-AML-001 studies, as well as the landmark AGILE phase III trial (NEJM 2022) showing that ivosidenib plus azacitidine significantly improved event-free survival and OS versus azacitidine alone in IDH1-mutated AML — leading to FDA approval of this combination. Dr. DiNardo has additionally contributed foundational work on venetoclax-based triplet combinations incorporating IDH inhibitors or FLT3 inhibitors, exploring novel all-oral regimens for AML. She has authored over 200 peer-reviewed publications, serves on the NCCN AML guidelines panel, and was named a "Rising Star" in hematology by Blood and ASCO.